FDA approves dispersible tablet formulation of dolutegravir for HIV in children

FDA approves dispersible tablet formulation of dolutegravir for HIV in children

Source: 
Pharmaceutical Business Review
snippet: 


ViiV Healthcare has been granted approval by the US Food and Drug Administration (FDA) for Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension for the treatment of human immunodeficiency virus type 1 (HIV-1) in infants and children.